Get Cash Back and $0 Commissions + The Power of TradeStation
Consolidated Research: 2019 Summary Expectations for Southern, Exelon, PriceSmart, Five Prime Therapeutics, Digi International, and Voyager Therapeutics Fundamental Analysis, Key Performance Indications
Globe Newswire 16-Jan-2019 7:40 AM
NEW YORK, Jan. 16, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Southern Company (NYSE:SO), Exelon Corporation (NYSE:EXC), PriceSmart, Inc. (NASDAQ:PSMT), Five Prime Therapeutics, Inc. (NASDAQ:FPRX), Digi International Inc. (NASDAQ:DGII), and Voyager Therapeutics, Inc. (NASDAQ:VYGR), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Market Source Research, available for free download at the links above, examine Southern Company (NYSE:SO), Exelon Corporation (NYSE:EXC), PriceSmart, Inc. (NASDAQ:PSMT), Five Prime Therapeutics, Inc. (NASDAQ:FPRX), Digi International Inc. (NASDAQ:DGII), and Voyager Therapeutics, Inc. (NASDAQ:VYGR) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed January 14th, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
SOUTHERN COMPANY (SO) REPORT OVERVIEW
Southern's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Southern reported revenue of $6,159.00MM vs $6,201.00MM (down 0.68%) and analysts estimated basic earnings per share $1.14 vs $1.07 (up 6.54%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Southern reported revenue of $23,031.00MM vs $19,896.00MM (up 15.76%) and analysts estimated basic earnings per share $0.84 vs $2.57 (down 67.32%). Analysts expect earnings to be released on February 20th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.51. The estimated EPS forecast for the next fiscal year is $3.01 and is expected to report on February 20th, 2019.
For the three months ended September 30th, 2018 vs September 30th, 2017, Exelon reported revenue of $9,403.00MM vs $8,768.00MM (up 7.24%) and analysts estimated basic earnings per share $0.76 vs $0.86 (down 11.63%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Exelon reported revenue of $33,531.00MM vs $31,360.00MM (up 6.92%) and analysts estimated basic earnings per share $3.98 vs $1.23 (up 223.58%). Analysts expect earnings to be released on February 6th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $0.55. The estimated EPS forecast for the next fiscal year is $3.14 and is expected to report on February 6th, 2019.
For the three months ended November 30th, 2018 vs November 30th, 2017, PriceSmart reported revenue of $779.64MM vs $767.07MM (up 1.64%) and analysts estimated basic earnings per share $0.48 vs $0.74 (down 35.14%). For the twelve months ended August 31st, 2018 vs August 31st, 2017, PriceSmart reported revenue of $3,166.70MM vs $2,996.63MM (up 5.68%) and analysts estimated basic earnings per share $2.44 vs $2.98 (down 18.12%). Analysts expect earnings to be released on April 4th, 2019. The report will be for the fiscal period ending February 28th, 2019. Reported EPS for the same quarter last year was $0.89. The estimated EPS forecast for the next fiscal year is $3.18 and is expected to report on October 24th, 2019.
FIVE PRIME THERAPEUTICS, INC. (FPRX) REPORT OVERVIEW
Five Prime Therapeutics' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Five Prime Therapeutics reported revenue of $5.77MM vs $8.33MM (down 30.75%) and basic earnings per share -$1.37 vs -$1.54. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Five Prime Therapeutics reported revenue of $39.51MM vs $30.69MM (up 28.73%) and analysts estimated basic earnings per share -$5.38 vs -$2.44. Analysts expect earnings to be released on February 26th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$1.04. The estimated EPS forecast for the next fiscal year is -$5.26 and is expected to report on February 26th, 2019.
For the three months ended September 30th, 2018 vs September 30th, 2017, Digi International reported revenue of $65.66MM vs $45.11MM (up 45.58%) and analysts estimated basic earnings per share $0.13 vs $0.16 (down 18.75%). For the twelve months ended September 30th, 2018 vs September 30th, 2017, Digi International reported revenue of $228.37MM vs $181.63MM (up 25.73%) and analysts estimated basic earnings per share $0.05 vs $0.35 (down 85.71%). Analysts expect earnings to be released on January 31st, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.07. The estimated EPS forecast for the next fiscal year is $0.46 and is expected to report on November 21st, 2019.
For the three months ended September 30th, 2018 vs September 30th, 2017, Voyager Therapeutics reported revenue of $2.09MM vs $1.15MM (up 82.40%) and analysts estimated basic earnings per share -$0.63 vs -$0.89. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Voyager Therapeutics reported revenue of $10.14MM vs $14.22MM (down 28.73%) and analysts estimated basic earnings per share -$2.64 vs -$1.59. Analysts expect earnings to be released on March 13th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.40. The estimated EPS forecast for the next fiscal year is -$2.92 and is expected to report on March 13th, 2019.
Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.
REGISTERED MEMBER STATUS
Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at compliance@MarketSourceResearch.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
